Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia

Schizophrenia Clinical Trial

Official title:

A Phase 1, Single Dose, Parallel Cohort Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TV-44749, Olanzapine for Extended-Release Injectable Suspension for Subcutaneous Use, in Chinese Patients With Schizophrenia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06253546
• Other study ID #: TV44749-PK-10188
• Status: Recruiting
• Phase: Phase 1
• Start date: March 28, 2024
• Est. completion date: January 31, 2025

Study information

• Verified date: May 2024
• Source: Teva Branded Pharmaceutical Products R&D, Inc.
• Contact: Teva U.S. Medical Information
• Phone: 1-888-483-8279
• Email: USMedInfo[@]tevapharm.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Primary Objective: To evaluate the safety and tolerability of single doses of TV-44749 for subcutaneous (sc) use in Chinese participants with schizophrenia. Secondary Objectives: - To evaluate the pharmacokinetics (PK) of single doses of TV-44749 administered sc. - To evaluate the pharmacokinetics of oral olanzapine tablets following multiple dose administration. - To monitor the safety and tolerability of multiple doses of oral olanzapine tablets given in the study.

Description:

The total study duration for participants is planned to be approximately 13 weeks, including 40 days of screening, 1-week oral olanzapine treatment, a 1-week washout period, 4-week TV-44749 treatment, and 2-week follow-up period after the last dosing interval.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 36
• Est. completion date: January 31, 2025
• Est. primary completion date: January 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

• Body weight >50 kg and body mass index (BMI) between 18.5 to 38.0 kg/m2, inclusive, at the time of screening.
• A current confirmed diagnosis of schizophrenia according to an evaluation by the investigator, using the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)
• Are clinically stable, on oral olanzapine (i.e., dose has not changed in the last 4 weeks), and not currently on other antipsychotic treatment at the time of screening.
• No hospitalization for worsening of schizophrenic symptoms and no significant exacerbation of schizophrenic symptoms, as judged by the investigator, within the 3 months prior to screening.
• Female participants must have a negative serum pregnancy test at screening, are sterile or postmenopausal, and not planning pregnancy within the study period and for an additional 6 months after last dose administration.
• Male participants must be surgically sterile, or, if capable of producing offspring, has exclusively same-sex partners or is currently using an approved method of birth control.
• Agree to maintain current smoking or nonsmoking status at the time informed consent is obtained and throughout the study until completion of the end of study (EOS)/early termination (ET) visit.
• Have no ongoing or expected significant life events (such as pending loss of housing, marital status change, long travel abroad, surgery, etc.) that could affect study outcomes expected throughout the period of study participation. NOTE: Additional criteria apply, please contact the investigator for more information.

Exclusion Criteria:

• Presence or have a history of clinically significant diseases of the renal, hepatic, gastrointestinal, cardiovascular, musculoskeletal system or presence or history of clinically significant immunological, endocrine, metabolic, neurological, or psychiatric disorder(s) (other than schizophrenia), or a history of any illness that, in the opinion of the principal investigator, might pose additional risk to the participant by participation in the study or confound the results of the study
• Major trauma or surgery in the 2 months before screening or at any time between screening and the first dose of the investigational medicinal product (IMP), surgery scheduled during the study or follow-up period, or open biopsy within 4 months prior to screening
• History of malignancy or treatment of malignancy in the last 5 years, excluding resected basal cell or squamous cell carcinoma of the skin. NOTE: Additional criteria apply, please contact the investigator for more information.

Related Conditions & MeSH terms

• Schizophrenia

Intervention

Drug:
• TV-44749
Pharmaceutical form: extended-release injectable suspension Route of administration: subcutaneous injection
• Oral Olanzapine
Pharmaceutical form: tablet Route of administration: oral

Locations

Country	Name	City	State
China	Teva Investigational Site 88048	Beijing
China	Teva Investigational Site 88049	Beijing
China	Teva Investigational Site 88047	Guangzhou
China	Teva Investigational Site 88046	Shanghai
China	Teva Investigational Site 88050	Wuhan Shi
China	Teva Investigational Site 88056	Xi'an Shi

Sponsors (1)

Lead Sponsor	Collaborator
Teva Branded Pharmaceutical Products R&D, Inc.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Period 2: Number of Participants with Treatment Emergent Adverse Events (TEAEs)		Day 1 Up to Day 43
Primary	Period 2: Number of Participants with Treatment Emergent Serious Adverse Events (SAEs)		Day 1 Up to Day 43
Primary	Period 2: Number of Participants with Injection Site Adverse Events		Day 1 Up to Day 43
Secondary	Period 2: Maximum Observed Plasma Drug Concentration (Cmax) of TV-44749		Day 1 Up to Day 43
Secondary	Period 2: Area Under the Plasma Drug Concentration versus Time Curve (AUC) of TV-44749		Day 1 Up to Day 43
Secondary	Period 2: AUC of TV-44749 Extrapolated to Infinity (AUC0-8)		Day 1 Up to Day 43
Secondary	Period 2: Time to Maximum Observed Concentration (Tmax) of TV-44749		Day 1 Up to Day 43
Secondary	Period 2: Apparent Elimination Half-Life (t½) of TV-44749		Day 1 Up to Day 43
Secondary	Period 1: Maximum Observed Plasma Drug concentration at Steady State (Cmax,ss[oral olanzapine])		Day 7
Secondary	Period 1: AUC of Oral Olanzapine at Steady State (AUC0-t,ss[oral olanzapine])		Day 7
Secondary	Period 1: Calculated AUC of Oral Olanzapine at Steady State Extrapolated Over 28 Days (AUC0-t,ss[oral olanzapine] × 28)		Day 7
Secondary	Period 1: Time to Maximum Concentration of Oral Olanzapine at Steady State (Tmax,ss[oral olanzapine])		Day 7
Secondary	Period 1: Number of Participants with TEAEs		Day 1 Up to Day 7
Secondary	Period 1: Number of Participants with Treatment Emergent SAEs		Day 1 Up to Day 7